HYpoxia-driven PROstate cancer GENomics (HYPROGEN)
Research type
Research Study
Full title
Illuminating the genomic landscape of hypoxia-driven early metastatic prostate cancer
IRAS ID
262789
Contact name
Robert Bristow
Contact email
Sponsor organisation
The Christie NHS Foundation Trust
Clinicaltrials.gov Identifier
CFTSp155, Sponsor Ref Number; 18_DOG04_201, Christie Ref Number
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Due to the rapid growth, tumour demand for oxygen often is higher than what can be delivered by the newly forming blood vessels. Tumour adaption to this imbalanced oxygen supply and demand (hypoxia) is associated with poor prognosis and genetic changes (genomic instability) that allow it to become more resistant to chemo- and radiotherapy. Patients with hypoxic tumours therefore die earlier. Limited information is available on hypoxia in newly diagnosed prostate cancer, especially to what degree hypoxia in the prostate tumour is associated with the presence of metastases to bones. This study will therefore aim to determine the association between hypoxia in the primary tumour with the presence of skeletal metastases. Secondly this study will aim to determine if hypoxia is also present in the metastatic sites themselves. Hypoxia presence will be determined by using a hypoxia identifying stain (by giving a patient a tablet of the stain to take orally) and by identifying genomic alterations that are associated with hypoxia. After taking the tablet of the hypoxia marker (Pimonidazol) patients will receive both a biopsy of the prostate and of one of the bone metastasis. Patients who already have undergone a diagnostic biopsy of the prostate may opt to not undergo a second biopsy solely for research purposes, in which case existing archival samples from the diagnostic biopsies willl be assessed to address the research questions. This will, however, limit the information contant to be retrieved from the study assessments. The presence or not as well as the degree of hypoxia in both sites will be assessed.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
19/NW/0569
Date of REC Opinion
24 Sep 2019
REC opinion
Favourable Opinion